AstraZeneca PLC (AZN)
NYQ · Drug Manufacturers - General
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Peers in Drug Manufacturers - General
All in industry →Eli Lilly and Company
Johnson & Johnson
AbbVie Inc.
Merck & Co., Inc.
Novartis AG
Amgen Inc.
Gilead Sciences, Inc.
Novo Nordisk A/S
Pfizer Inc.
Bristol-Myers Squibb Company
Recent press releases
April 2026
AstraZeneca Board Member Rene Haas Steps Down for SoftBank CEO Role
# 🧾 What This Document Is This is a **Form 6-K**, a standard monthly report that foreign companies listed on U.S. exchanges (like AstraZeneca on the NYSE) must file with the SEC. It’s used to announce important company news to the public. This specific filing from **April 2026** contains one key an
AZN reports primary endpoint success for Ultomiris in IgAN study
# 📜 What This Document Is 📰 This document is a Form 6-K, which is a report filed with the U.S. Securities and Exchange Commission (SEC) by a foreign private issuer. Simply put, it’s a detailed update designed to keep investors informed about major corporate events or clinical trial results that h
AZN Tozorakimab Meets Endpoint for COPD Exacerbation Reduction
# 🧾 Form 6-K 📑 What This Document Is This document is a Form 6-K, which is a mandatory filing that allows AstraZeneca PLC, a foreign-listed company, to report major, timely updates to U.S. investors. Because it's an interim filing, it’s not a quarterly or annual report, but rather an announcement
AstraZeneca Shareholders Approve Share Buyback and Board Powers at AGM
# 🧾 What This Document Is This is a **Form 6-K**, a standard report that a foreign company listed on U.S. exchanges (like the London Stock Exchange) must file with the SEC. Think of it as an official news update for American investors. The big news here? AstraZeneca just held its **Annual General
ASTRAZENECA PLC — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a report foreign companies like AstraZeneca file with the SEC to share important news with U.S. investors. This specific report, dated April 2, 2026, is a press release announcing **positive results from a major Phase III clinical trial** called EME
ASTRAZENECA PLC — 6-K Filing
# 🔖 What This Document Is This is a **Form 6-K**, a standard monthly report that foreign companies listed in the U.S. must file with the SEC. Think of it as a routine update from AstraZeneca to its American investors. This specific filing contains two official notifications required by UK regulator
March 2026
ASTRAZENECA PLC — 6-K Filing
# 🔖 What This Document Is This is a **Form 6-K**, a report that foreign companies listed on U.S. exchanges (like AstraZeneca) use to quickly release material news to the market. This specific filing, dated March 31, 2026, is a clinical trial results announcement. It contains "inside information," m
SEC filings
All filings →Insider trades
All insider trades →AstraZeneca PLC has no reported insider trades in the last 90 days.